Dermatophyte infections
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
tinea capitis
systemic antifungal therapy
Oral systemic antifungal therapy is necessary. Topical agents are not effective as they do not penetrate the hair shaft, where the fungal infection resides.
Griseofulvin is considered the gold standard treatment for Microsporum infections and terbinafine is considered the gold standard treatment for Trichophyton infections.[23]Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014 Sep;171(3):454-63. http://onlinelibrary.wiley.com/doi/10.1111/bjd.13196/full http://www.ncbi.nlm.nih.gov/pubmed/25234064?tool=bestpractice.com [31]Tey HL, Tan AS, Chan YC. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011 Apr;64(4):663-70. http://www.ncbi.nlm.nih.gov/pubmed/21334096?tool=bestpractice.com [32]Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016 May 12;(5):CD004685. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004685.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/27169520?tool=bestpractice.com In the case of Trichophyton rubrum syndrome, antifungals are to be used for a longer period, and can go up to 3 months. Sometimes they may have to be combined with other antifungals.[21]Rajagopalan M, Inamadar A, Mittal A, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018 Jul 24;18(1):6. https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0073-1 http://www.ncbi.nlm.nih.gov/pubmed/30041646?tool=bestpractice.com
Griseofulvin is better absorbed with a fatty meal and is taken once daily, but is fungistatic and requires 8 to 10 weeks of therapy for cure.[23]Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014 Sep;171(3):454-63. http://onlinelibrary.wiley.com/doi/10.1111/bjd.13196/full http://www.ncbi.nlm.nih.gov/pubmed/25234064?tool=bestpractice.com [30]Gupta AK, Cooper EA, Bowen JE, et al. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. J Drugs Dermatol. 2008 Apr;7(4):369-72. http://www.ncbi.nlm.nih.gov/pubmed/18459518?tool=bestpractice.com [56]Friedlander SF. The optimal therapy for tinea capitis. Pediatr Dermatol. 2000 Jul-Aug;17(4):325-6. http://www.ncbi.nlm.nih.gov/pubmed/10990588?tool=bestpractice.com [57]Elewski BE. Treatment of tinea capitis: beyond griseofulvin. J Am Acad Dermatol. 1999 Jun;40(6 Pt 2):S27-30. http://www.ncbi.nlm.nih.gov/pubmed/10367913?tool=bestpractice.com
Fluconazole is not approved for tinea capitis; however, it is sometimes used off-label in refractory cases in exceptional circumstances. Its use is limited by adverse effects. It may cause abdominal adverse effects and rare hepatotoxicity in children.[23]Fuller LC, Barton RC, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol. 2014 Sep;171(3):454-63. http://onlinelibrary.wiley.com/doi/10.1111/bjd.13196/full http://www.ncbi.nlm.nih.gov/pubmed/25234064?tool=bestpractice.com
Primary options
griseofulvin microsize: children ≥2 years of age: 10-20 mg/kg/day orally given in 1-4 divided doses for 4-6 weeks, maximum 1000 mg/day; adults: 500-1000 mg/day orally given in 1-4 divided doses for 4-6 weeks
OR
terbinafine: children ≥4 years of age and body weight <25 kg: 125 mg orally once daily for 6 weeks; children ≥4 years of age and body weight 25-35 kg: 187.5 mg orally once daily for 6 weeks; children ≥4 years of age and body weight >35 kg: 250 mg orally once daily for 6 weeks; adults: 250 mg orally once daily for 6 weeks
Secondary options
itraconazole: children: 5-10 mg/kg/day orally given in 1-2 divided doses for 4-6 weeks, maximum 600 mg/day; adults: 200 mg orally once or twice daily for 4-6 weeks
OR
fluconazole: children: 3-6 mg/kg/day orally for 6 weeks; adults: 200 mg orally once daily for 6 weeks
topical antifungal shampoo
Additional treatment recommended for SOME patients in selected patient group
Topical therapy is useful to reduce the likelihood of spread of tinea capitis to siblings or classmates; in situations where a widespread daycare or school outbreak occurs, topical therapy may shorten the time in which viable dermatophytes may be spread through use of shared clothing or grooming items.
Primary options
selenium sulfide topical: (1 to 2.5% shampoo) children and adults: apply to scalp twice weekly for 2 weeks, leave each application on scalp for 2-3 minutes then rinse
OR
ketoconazole topical: (1-2% shampoo) children: apply to scalp two to three times weekly for 2-4 weeks, leave each application on scalp for 5 minutes then rinse; adults: apply to scalp twice weekly for 4 weeks, leave each application on scalp for 5 minutes then rinse
tinea barbae, tinea manuum, or Majocchi's granuloma
systemic antifungal therapy
Similar to tinea capitis, systemic therapy is needed to deliver effective antifungal therapy to the hair shaft, where the infection resides in tinea barbae, or the thick, keratinised skin of the palmar surface of the hand(s).
When tinea manuum is associated with tinea unguium of the fingernails, longer treatment times of 8 to 12 weeks are necessary.
Majocchi's granuloma is a fungal infection in hair, hair follicles, and surrounding skin that also requires systemic antifungal therapy for cure.
Primary options
griseofulvin: adults: 500-1000 mg/day orally given in 1-2 divided doses for 4-8 weeks
OR
terbinafine: adults: 250 mg orally once daily for 6 weeks
OR
itraconazole: adults: 200 mg orally once daily for 2-4 weeks
Secondary options
fluconazole: adults: 200 mg orally once daily for 2-4 weeks
tinea faciale, tinea corporis, tinea cruris, or tinea pedis
topical allylamine antifungal therapy
These types of dermatophytosis are generally found in superficial skin structures and are usually responsive to topical therapy.
There is limited evidence to favour the allylamine group (e.g., terbinafine, naftifine, butenafine) for topical therapy.[37]Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001434. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001434.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/17636672?tool=bestpractice.com [38]Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013 Mar;149(3):341-9. http://www.ncbi.nlm.nih.gov/pubmed/23553036?tool=bestpractice.com A higher-strength formulation of naftifine has been tried for tinea cruris and tinea pedis.[39]Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011 Oct;10(10):1142-7. http://www.ncbi.nlm.nih.gov/pubmed/21968664?tool=bestpractice.com [40]Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011 Nov;10(11):1282-8. http://www.ncbi.nlm.nih.gov/pubmed/22052309?tool=bestpractice.com [41]El-Gohary M, van Zuuren EJ, Fedorowicz Z, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014 Aug 4;(8):CD009992. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009992.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/25090020?tool=bestpractice.com [42]Gold M, Dhawan S, Verma A, et al. Efficacy and safety of naftifine HCl cream 2% in the treatment of pediatric subjects with tinea corporis. J Drugs Dermatol. 2016 Jun 1;15(6):743-8. http://www.ncbi.nlm.nih.gov/pubmed/27272083?tool=bestpractice.com Two weeks of treatment with the 2% strength was as effective as 4 weeks of treatment with the 1% formulation in the management of tinea pedis.[40]Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011 Nov;10(11):1282-8. http://www.ncbi.nlm.nih.gov/pubmed/22052309?tool=bestpractice.com
Apply topical agents until no further infection is visible and for 1 to 2 weeks after, generally a total treatment time of 2 to 6 weeks, depending on the topical agent.
Tinea pedis can be difficult to eradicate or may easily recur if there is a reservoir of infection in the toenails, or inadequate application of antifungal therapy to the entire surface of the foot and sides in moccasin-type tinea pedis. Disinfection of footwear or replacement footwear at the time of treatment may reduce recurrence of tinea pedis. In moccasin-type tinea pedis also spread the topical agent along the sole and sides of the feet.
Primary options
terbinafine topical: (1%) children ≥12 years of age and adults: apply to the affected area(s) once daily (tinea corporis or tinea cruris) or twice daily (tinea pedis) for 1-4 weeks
OR
naftifine topical: (1% gel) adults: apply to the affected area(s) twice daily for up to 4 weeks; (1% cream) adults: apply to the affected area(s) once daily for up to 4 weeks; (2% cream or gel) children ≥12 years of age and adults: apply to the affected area(s) once daily for 2 weeks
OR
butenafine topical: (1%) children ≥12 years of age and adults: apply to the affected area(s) once or twice daily for 1-2 weeks
topical aluminium acetate
Additional treatment recommended for SOME patients in selected patient group
If the patient has vesiculobullous tinea pedis, recommend the application of topical aluminium acetate soaks several times daily for relief of pain and tenderness until the resolution of bullae and open skin with serous discharge.
Primary options
aluminium acetate topical: children and adults: soak twice daily for 15-30 minutes for 7 days
other topical antifungal therapy
Topical azoles, ciclopirox, or tolnaftate are less preferred and are typically second-line agents.
Azole therapy has been demonstrated to be better than placebo in tinea pedis.[58]Hart R, Bell-Syer SE, Crawford F, et al. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ. 1999 Jul 10;319(7202):79-82. http://www.ncbi.nlm.nih.gov/pubmed/10398626?tool=bestpractice.com [59]Bell-Syer SE, Hart R, Crawford F, et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatolog Treat. 2001 Jun;12(2):69-74. http://www.ncbi.nlm.nih.gov/pubmed/12243661?tool=bestpractice.com
Apply topical agents until no further infection is visible and for 1 to 2 weeks after, generally a total treatment time of 2 to 6 weeks depending on the topical agent.
Tinea pedis can be difficult to eradicate or may easily recur if there is a reservoir of infection in the toenails, or inadequate application of antifungal therapy to the entire surface of the foot and sides in moccasin-type tinea pedis. Disinfection of footwear or replacement footwear at the time of treatment may reduce recurrence of tinea pedis. In moccasin-type tinea pedis also spread the topical agent along the sole and sides of the feet.
Primary options
miconazole topical: (2%) children ≥2 years of age and adults: apply to the affected area(s) twice daily for 2-4 weeks
OR
clotrimazole topical: (1%) children ≥2 years of age and adults: apply to the affected area(s) twice daily for 2-4 weeks
OR
econazole topical: (1%) children and adults: apply to the affected area(s) once daily for 2 weeks
OR
ketoconazole topical: (2%) children and adults: apply to the affected area(s) once daily for 2-6 weeks
OR
luliconazole topical: (1%) children ≥2 years of age and adults: apply to the affected area(s) once daily for 1-2 weeks
OR
tolnaftate topical: (1%) children and adults: apply to the affected area(s) twice daily for 2-4 weeks
OR
ciclopirox topical: (0.77%) children ≥10 years of age and adults: apply to the affected area(s) twice daily for 1-4 weeks
topical aluminium acetate
Additional treatment recommended for SOME patients in selected patient group
If the patient has vesiculobullous tinea pedis, recommend the application of topical aluminium acetate soaks several times daily for relief of pain and tenderness until the resolution of bullae and open skin with serous discharge.
Primary options
aluminium acetate topical: children and adults: soak twice daily for 15-30 minutes for 7 days
systemic antifungal therapy
Systemic antifungal therapy may be needed, particularly in immunosuppressed individuals with extensive tinea pedis.
In case of systemic antifungal agents, terbinafine is recommended in treatment-naive cases of tinea pedis, while itraconazole is recommended in recalcitrant and severe cases. The minimum treatment duration should be 2 to 4 weeks in treatment-naive tinea pedis and >4 weeks in recalcitrant cases.[21]Rajagopalan M, Inamadar A, Mittal A, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018 Jul 24;18(1):6. https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0073-1 http://www.ncbi.nlm.nih.gov/pubmed/30041646?tool=bestpractice.com
Evidence suggests that systemic therapy with terbinafine, itraconazole, griseofulvin, or fluconazole may be considered as alternative treatment for patients with tinea corporis with extensive skin involvement, or patients who are refractory to topical therapy. Treatment duration is usually 2 to 4 weeks but depends on response. A longer course may be required in recalcitrant cases.[43]Leung AK, Lam JM, Leong KF, et al. Tinea corporis: an updated review. Drugs Context. 2020;9:2020-5-6. https://www.drugsincontext.com/tinea-corporis:-an-updated-review http://www.ncbi.nlm.nih.gov/pubmed/32742295?tool=bestpractice.com
Failure of treatment of tinea faciale or faciei, tinea cruris, tinea pedis, or tinea corporis may be due to patient non-adherence to treatment recommendations, misdiagnosis, or immunosuppressive illness or therapy. With treatment failure, a search for these possibilities and/or dermatological consultation may be warranted.
Primary options
terbinafine: children ≥2 years of age: consult specialist for guidance on dose; adults: 250 mg orally once daily
OR
itraconazole: children: consult specialist for guidance on dose; adults: 200-400 mg/day orally given in 1-2 divided doses
OR
griseofulvin microsize: children ≥2 years of age: consult specialist for guidance on dose; adults: 500-1000 mg/day orally given in 1-4 divided doses
OR
fluconazole: children: consult specialist for guidance on dose; adults: 150-200 mg orally once weekly
topical aluminum acetate
Additional treatment recommended for SOME patients in selected patient group
If the patient has vesiculobullous tinea pedis, recommend the application of topical aluminium acetate soaks several times daily for relief of pain and tenderness until the resolution of bullae and open skin with serous discharge.
Primary options
aluminium acetate topical: children and adults: soak twice daily for 15-30 minutes for 7 days
tinea unguium (onychomycosis)
systemic terbinafine therapy
Do not start treatment before mycological confirmation of infection.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com
Systemic antifungal treatment is recommended for most patients. Both terbinafine and azoles have been found to be effective in achieving a normal-looking nail and curing the toenail infection, with terbinafine being more effective than azoles; therefore, consider terbinafine as first-line treatment.[44]de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Feb;15(1):17-36.
http://www.ncbi.nlm.nih.gov/pubmed/24352873?tool=bestpractice.com
[45]Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat. 2012 Dec;23(6):449-52.
http://www.ncbi.nlm.nih.gov/pubmed/21801094?tool=bestpractice.com
[46]Kreijkamp-Kaspers S, Hawke K, Guo L, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017 Jul 14;(7):CD010031.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010031.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/28707751?tool=bestpractice.com
[ ]
How do oral antifungal medications compare in people with toenail onychomycosis?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1875/fullShow me the answer
Toenail infections require a longer duration of therapy than fingernails due to the slower rate of nail growth. One systematic review found that continuous terbinafine for 24 weeks, but not 12 weeks, was significantly more likely to result in mycological cure than continuous itraconazole for 12 weeks or weekly fluconazole for 9 to 12 months.[47]Gupta AK, Stec N, Bamimore MA, et al. The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol. 2020 Mar;34(3):580-8. http://www.ncbi.nlm.nih.gov/pubmed/31746067?tool=bestpractice.com
Patient expectations regarding the success of therapy should be discussed before starting treatment. Counsel patients about regularly alternating footwear, avoiding walking barefoot in public bathing areas, and avoiding trauma to the infected nail.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com
Primary options
terbinafine: children: consult specialist for guidance on dose; adults: 250 mg orally once daily for 12 weeks (toenails) or 6 weeks (fingernails)
systemic azole therapy or topical treatment
Do not start treatment before mycological confirmation of infection.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com
Systemic treatment is recommended for most patients. Itraconazole and fluconazole are second-line options; adverse-effect profile and cost determine which is the most appropriate choice.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com Toenail infections require a longer duration of therapy than fingernails due to the slower rate of nail growth.
For a small number of patients with very distal infection or superficial white onychomycosis, mechanical debridement followed by topical treatment may suffice.[49]Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol. 2004 Jun;140(6):696-701. https://jamanetwork.com/journals/jamadermatology/fullarticle/480625 http://www.ncbi.nlm.nih.gov/pubmed/15210460?tool=bestpractice.com Although some evidence supports the use of topical treatments for fungal infections of the toenails, complete cure rates are relatively low.[50]Foley K, Gupta AK, Versteeg S, et al. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020 Jan 16;(1):CD012093. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/31978269?tool=bestpractice.com Efinaconazole and tavaborole topical solutions have been reported to effectively treat toenail onychomycosis in randomised, vehicle-controlled trials.[51]Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 Apr;68(4):600-8. http://www.ncbi.nlm.nih.gov/pubmed/23177180?tool=bestpractice.com [52]Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015 Jul;73(1):62-9. http://www.jaad.org/article/S0190-9622%2815%2901512-1/fulltext http://www.ncbi.nlm.nih.gov/pubmed/25956661?tool=bestpractice.com [53]Gupta AK, Hall S, Zane LT, et al. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. J Dermatolog Treat. 2018 Feb;29(1):44-8. http://www.ncbi.nlm.nih.gov/pubmed/28521541?tool=bestpractice.com Both are approved by the US Food and Drug Administration for the treatment of toenail distal subungual onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. One Cochrane review confirmed the effectiveness of efinaconazole and tavaborole topical solutions, and that of ciclopirox nail lacquer.[50]Foley K, Gupta AK, Versteeg S, et al. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020 Jan 16;(1):CD012093. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/31978269?tool=bestpractice.com The effectiveness of ciclopirox nail lacquer is enhanced when delivered in a water-soluble biopolymer vehicle.[50]Foley K, Gupta AK, Versteeg S, et al. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020 Jan 16;(1):CD012093. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/31978269?tool=bestpractice.com [54]Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):773-81. http://www.ncbi.nlm.nih.gov/pubmed/19453778?tool=bestpractice.com Ciclopirox nail lacquer requires debridement of hyperkeratotic nail for best effect.[55]Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S70-80. http://www.ncbi.nlm.nih.gov/pubmed/11051136?tool=bestpractice.com
Patient expectations regarding the success of therapy should be discussed before starting treatment. Counsel patients about regularly alternating footwear, avoiding walking barefoot in public bathing areas, and avoiding trauma to the infected nail.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com
Primary options
itraconazole: children: consult specialist for guidance on dose; adults: 200 mg orally twice daily for 7 days, followed by no treatment for 21 days, then 200 mg twice daily for 7 days (fingernails); adults: 200 mg orally once daily for 12 weeks (toenails)
OR
fluconazole: children: consult specialist for guidance on dose; adults: 150-450 mg orally once weekly for 6-12 months (toenails) or 3-6 months (fingernails)
Secondary options
ciclopirox topical: (8%) children ≥12 years of age and adults: apply to affected nail(s) once daily, remove with acetone every 7 days and repeat application cycle
OR
efinaconazole topical: (10%) children ≥6 years of age and adults: apply to the affected nail(s) once daily for 48 weeks
OR
tavaborole topical: (5%) children ≥6 years of age and adults: apply to the affected nail(s) once daily for 48 weeks
additional course of alternative systemic therapy
Only 30% to 60% of people will report a clinical cure following treatment with oral antifungals.[48]Kreijkamp-Kaspers S, Hawke KL, van Driel ML. Oral medications to treat toenail fungal infection. JAMA. 2018 Jan 23;319(4):397-8. http://www.ncbi.nlm.nih.gov/pubmed/29362778?tool=bestpractice.com
Review diagnostic findings to ensure that a differential diagnosis or concomitant condition does not explain nail change. Only consider a second course of oral treatment after confirming diagnosis, and ensure that an agent other than the one used for initial treatment is used.
Patient expectations regarding the success of therapy should be discussed before starting treatment. Counsel patients about regularly alternating footwear, avoiding walking barefoot in public bathing areas, and avoiding trauma to the infected nail.[13]Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937-58. https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358 http://www.ncbi.nlm.nih.gov/pubmed/25409999?tool=bestpractice.com
Primary options
terbinafine: children: consult specialist for guidance on dose; adults: 250 mg orally once daily for 12 weeks (toenails) or 6 weeks (fingernails)
Secondary options
itraconazole: children: consult specialist for guidance on dose; adults: 200 mg orally twice daily for 7 days, followed by no treatment for 21 days, then 200 mg twice daily for 7 days (fingernails); adults: 200 mg orally once daily for 12 weeks (toenails)
OR
fluconazole: children: consult specialist for guidance on dose; adults: 150-450 mg orally once weekly for 6-12 months (toenails) or 3-6 months (fingernails)
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer